Parabilis Medicines: Funding, Investors & Team (Oct 2026)
Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced a novel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.
Parabilis Medicines has raised $380M across 2 funding rounds on record, the most recent an undisclosed round of $75.0M announced in Jun 2026.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Parabilis Medicines Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Parabilis Medicines Funding Rounds
Parabilis Medicines raised $305M in a Series F announced in Jan 2026.
5 months later, an undisclosed round of $75.0M was announced in Jun 2026.
Parabilis Medicines Founders and Leadership Team
No contact details are on record for this team yet.
Parabilis Medicines Funding Compared to Other Biotechnology Startups
Parabilis Medicines' latest round of $75.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Parabilis Medicines in Biotechnology and Cambridge
Companies Similar to Parabilis Medicines
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Parabilis Medicines Funding FAQs
What does Parabilis Medicines do?
Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced a novel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.
How much funding has Parabilis Medicines raised?
Parabilis Medicines has raised $380M across 2 rounds on record. The most recent is an undisclosed round of $75.0M announced in Jun 2026.
When did Parabilis Medicines last raise funding?
Parabilis Medicines' most recent funding round on record is an undisclosed round of $75.0M, announced in Jun 2026.
Who founded Parabilis Medicines?
FundedIQ lists Mathai Mammen (Founder), Weiqing Zhou (Founder) at Parabilis Medicines.
Where is Parabilis Medicines headquartered?
Parabilis Medicines is based in Cambridge, Massachusetts, United States.
How many employees does Parabilis Medicines have?
Parabilis Medicines is in the 101-250 employee band.
How does Parabilis Medicines' funding compare to other Biotechnology startups?
Parabilis Medicines' latest round of $75.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Parabilis Medicines Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Parabilis Medicines is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.